Methods and products for transfecting cells

Patent metadata

Field	Value
Publication number	US-9605277-B2
Application number	US-201615207167-A
Country	US
Kind code	B2
Filing date	Jul 11, 2016
Priority date	Dec 5, 2011
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

First claim

What is claimed is:

1. A method for treating HIV infection in a human subject, comprising:
(a) harvesting a hematopoietic cell from the subject;
(b) gene-editing the hematopoietic cell by transfecting the hematopoietic cell with an in vitro transcribed synthetic RNA molecule encoding a gene-editing protein, wherein
the hematopoietic cell expresses the gene-editing protein, and
the gene-editing protein comprises a DNA-binding domain and a nuclease catalytic domain that causes a double-strand break in the DNA of the hematopoietic cell to reduce the function of a gene selected from CCR5 and CXCR4; and

(c) administering the gene-edited hematopoietic cell to the subject to result in the treatment of HIV infection in the subject.

2. The method of claim 1 , wherein the gene-editing protein is selected from a TALEN and a zinc finger nuclease.

3. The method of claim 1 , wherein the in vitro transcribed synthetic RNA molecule further comprises one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.

4. The method of claim 1 , wherein the double-strand break is within about 5,000,000 bases of the transcription start site of the CCR5 or CXCR4 gene.

5. The method of claim 1 , wherein the method confers resistance to HIV infection in the subject.

6. The method of claim 1 , wherein the subject is infected with HIV.

7. The method of claim 1 , wherein the subject is afflicted with AIDS.

8. The method of claim 1 , wherein the hematopoietic cell is a hematopoietic stem cell.

9. The method of claim 1 , wherein the hematopoietic cell is a white blood cell.

Assignees

• Factor Bioscience Inc
• Factor Bioscience Inc

Inventors

• Angel Matthew
• Rohde Christopher

Classifications

• A61P31/18

  for HIV · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/06

  Antianaemics · CPC title